Company Overview of Valeant Canada Ltd.
Valeant Canada Ltd., a specialty pharmaceutical company, manufactures, distributes, and markets pharmaceutical products in the fields of neurology, psychiatry, pain management, and dermatology. It also focuses on neurology, such as pain management, Parkinson's disease, Epilepsy, multiple sclerosis, Huntington's disease, and ALS; infectious diseases, which include Hepatitis, HIV, SARS, and RSV; Dermatology, including Psoriasis, Eczema, Acne, Rosacea, Actinic Keratoses, Squamous Cell Carcinoma, and anti-fungals; and sleep disorders. Valeant Canada Ltd. was formerly known as ICN Canada Ltd and changed its name to Valeant Canada Ltd. in September 2004. The company was founded in 1956 and is base...
4787 Levy Street
Montreal, QC H4R 2P9
Founded in 1956
Key Executives for Valeant Canada Ltd.
Chairman of Valeant Pharmaceuticals International and CEO of Valeant Pharmaceuticals International
Compensation as of Fiscal Year 2017.
Valeant Canada Ltd. Key Developments
Valeant Plans to Split its Business into Three Segments
Aug 11 16
Valeant announced that it was planning to split its business into three segments: the so-called "durable growth" segment will incorporate the Bausch & Lomb eyecare business and most of the company's international sales; the "growth" segment will incorporate its Salix and Dendreon subsidiaries as well as its dermatology businesses; while the "cash-generating" segment will include neurology and other drugs.
Valeant Canada Expands its Canadian Manufacturing and Export Capacity
Jun 21 16
Valeant Canada is expanding its Canadian manufacturing and export capacity. The company is investing a total of USD 27.5 million in its Steinbach, Manitoba and Laval, Quebec manufacturing facilities. It will invest USD 15 million at Steinbach by the end of 2016, including USD 7 million in upgrades to product manufacturing technology and USD 8 million for the transfer of North American production of Xifaxan (rifaximin) and Apriso (mesalamine). The funds are intended to support the facility's growth and expand its role as an exporter of healthcare products, while ensuring robust security for products traveling through international distribution channels. Xifaxan is prescribed to relieve symptoms of hepatic encephalopathy and irritable bowel syndrome and Apriso is used to treat ulcerative colitis. Valeant also announced USD 12.5 million of investments in its Laval, Quebec facility, which includes USD 10 million to upgrade product manufacturing technology, as well as USD 2.5 million associated with the transfer of production of Arestin (minocycline hydrochloride), an antibiotic treatment for periodontal disease, to Laval.
Valeant Canada Announces Investment of $10 Million in Laval Facility to Increase and Secure its Export Capacity
Jun 13 16
Valeant Canada continued the expansion of its Canadian manufacturing and export capacity with a $10 million investment in its Laval, Quebec headquarters to enhance the site's manufacturing and export capabilities. The fourth notable investment announcement by Valeant in Canada in recent weeks, includes modernization of the plant with enhanced manufacturing technology to ensure robust security of Valeant-manufactured products as they move through international distribution channels. The investment announced in Laval plant will ensure compliance with U.S. regulatory requirements and maintain the facility's ability to service significant North American manufacturing mandates. It currently exports 75% of its products into markets across the continent. The upgrades for product manufacturing will take place by the end of 2016.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|